--- title: "Beijing Sl Pharmaceutical Co.,Ltd. (002038.SZ)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/002038.SZ.md" symbol: "002038.SZ" name: "Beijing Sl Pharmaceutical Co.,Ltd." industry: "Biotechnology" datetime: "2026-05-19T23:55:54.413Z" locales: - [en](https://longbridge.com/en/quote/002038.SZ.md) - [zh-CN](https://longbridge.com/zh-CN/quote/002038.SZ.md) - [zh-HK](https://longbridge.com/zh-HK/quote/002038.SZ.md) --- # Beijing Sl Pharmaceutical Co.,Ltd. (002038.SZ) ## Company Overview Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsenic trioxide; thymopentin; paclitaxel injection; docetaxel injection; vinorelbine tartrate injection; asparaginase; calcium folinate; gemcitabine hydrochloride; regorafenib tablets; oseltamivir phosphate capsules; ornidazole injection; adefovir dipivoxil capsules/adefovir dipivoxil tablets; ribavirin; valacyclovir hydrochloride; levofloxacin hydrochlorid; tenofovir disoproxil fumarate; cyclosporin injection/cyclosporin soft capsules; mycophenolate mofetil dispersible; coenzyme complex; enoxaparin sodium; simvastatin; telmisartan amlodipine; liposon; nitroglycerin spray; eptifibatide, argatroban; voglibose; dapagliflozin; vildagliptin; granisetron hydrochloride injection; omeprazole enteric-coated capsules; adenosylmethionine butanedisulfonate; cytidine triphosphate disodium injection cytidine triphosphate disodium injection; gabapentin; risedronate sodium; salmon calcitonin injection; lucosamine sulfate capsules; loratadine dispersible; desloratadine; naftopidil; somatostatin for injection; octreotide acetate; and etodolac sustained-release tablets. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | CN Market | | Website | [www.slpharm.com.cn](https://www.slpharm.com.cn) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:08.000Z **Overall: D (0.60)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 72 / 81 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 1.26% | | | Net Profit YoY | -387.91% | | | P/B Ratio | 1.26 | | | Dividend Ratio | 0.32% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 6414806060.76 | | | Revenue | 591023688.12 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -8.95% | D | | Profit Margin | -81.02% | E | | Gross Margin | 63.62% | A | | Revenue YoY | 1.26% | C | | Net Profit YoY | -387.91% | E | | Total Assets YoY | -3.76% | D | | Net Assets YoY | -9.33% | D | | Cash Flow Margin | -77.68% | E | | OCF YoY | 1.26% | C | | Turnover | 0.10 | E | | Gearing Ratio | 12.60% | A | ```chart-data:radar { "title": "Longbridge Financial Score - Beijing Sl Pharmaceutical Co.,Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "1.26%", "rating": "" }, { "name": "Net Profit YoY", "value": "-387.91%", "rating": "" }, { "name": "P/B Ratio", "value": "1.26", "rating": "" }, { "name": "Dividend Ratio", "value": "0.32%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "6414806060.76", "rating": "" }, { "name": "Revenue", "value": "591023688.12", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-8.95%", "rating": "D" }, { "name": "Profit Margin", "value": "-81.02%", "rating": "E" }, { "name": "Gross Margin", "value": "63.62%", "rating": "A" }, { "name": "Revenue YoY", "value": "1.26%", "rating": "C" }, { "name": "Net Profit YoY", "value": "-387.91%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-3.76%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-9.33%", "rating": "D" }, { "name": "Cash Flow Margin", "value": "-77.68%", "rating": "E" }, { "name": "OCF YoY", "value": "1.26%", "rating": "C" }, { "name": "Turnover", "value": "0.10", "rating": "E" }, { "name": "Gearing Ratio", "value": "12.60%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -13.46 | 50/81 | 425.29 | 94.56 | 81.07 | | PB | 1.27 | 7/81 | 1.42 | 1.35 | 1.26 | | PS (TTM) | 10.91 | 49/81 | 13.96 | 13.23 | 11.75 | | Dividend Yield | 0.32% | 33/81 | 0.32% | 0.27% | 0.25% | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A | | 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A | | 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B | | 04 | RemeGen (688331.SH) | A | A | C | C | B | B | | 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002038.SZ/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002038.SZ/norm.md) - [Related News](https://longbridge.com/en/quote/002038.SZ/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002038.SZ/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**